Blau Farmacêutica (BLAU3) Q1 2025 earnings summary

Executive summary

• Net revenue grew 4% year-over-year in Q1 2025 to BRL 373 million, driven by 15% growth in the private hospital segment and offset by a 24% decline in retail, aesthetics, and plasma due to temporary factors.

• Recurring net income increased 50% year-over-year to BRL 63 million, with gross margin improving to 40.1%, up 680 bps, and recurring EBITDA up 28% to BRL 83 million.

• Net income surged 129% to BRL 91 million, positively impacted by a one-time sale of a Botulinum Toxin registration.

• Investments in biotechnology, monoclonal antibodies, and capacity expansion rose 55% to BRL 73 million, with 14 new product registrations, mostly in Latin America.

• Maintained leadership in the onco-hematology market, serving over 9,500 institutions with a diverse portfolio.

Financial highlights

• Gross margin reached 40.1% (+680 bps YoY); recurring EBITDA margin at 22.2% (+420 bps YoY); recurring net margin at 16.9% (+520 bps YoY).

• Net debt fell to BRL 67 million (down 43% YoY), with leverage at 0.2x (down from 0.3x in 1Q24).

• Working capital as a percentage of net revenue rose from 45% to 48% due to inventory buildup and revenue timing, but working capital value fell by BRL 37 million YoY.

• Free cash flow to equity was negative BRL 27 million, reflecting higher investments and working capital needs.

• Dividend of BRL 45 million declared for tax efficiency.

Outlook and guidance

• Confident in delivering the annual plan, with medium and long-term prospects strong due to capacity expansion and a robust product pipeline, especially in biologics.

• Launch pipeline expected to accelerate, with BRL 700 million in new market value targeted for 2025 and at least BRL 3 billion over the next three years.

• Monoclonal antibody launches could double incremental TAM to BRL 6 billion between 2028 and 2030.

• Management expects normalization in retail, aesthetics, and plasma segments and resumed plasma sales in 2Q25.

• First revenue from Pernambuco plant achieved, expected to drive competitiveness and future growth.